Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

OptiBiotix Health PLC inks second deal for Sweetbiotix

OptiBiotix Health PLC, the life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has signed a second collaboration agreement with an arm of the Spanish National Research Council.
OptiBiotix Health PLC inks second deal for Sweetbiotix
The AIM-listed group’s initial research tie up the IQOG started in September 2015 and was designed to create sweet, low calorie sugars using different bacterial strains..

OptiBiotix Health PLC (LON:OPTI), the life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has signed a second collaboration agreement with an arm of the Spanish National Research Council.

The programme being undertaken by the Instituto de Química Orgánica General will assess the potential for incorporating natural sweeteners into existing or new sugar chains called oligosaccharides.

The ultimate aim is to create sweet products with functional health benefits.

The AIM-listed group’s initial research tie up the IQOG started in September 2015 and was designed to create sweet, low calorie sugars using different bacterial strains.

OptiBiotix's specialism is using the human microbiome, found in the gut and on the skin, to create treatments for time-bomb problems related to obesity.

“The sugar development programmes have the potential to address a key requirement in the food industry, addressing international concerns over the impact of sugar on obesity, highlighted by the recent announcement of a UK sugar tax,” said Stephen O’Hara, chief executive of the AIM-listed business.

“If successful, this research creates the prospect of replacing 'unhealthy' sugars in existing products with non digestible, low calorie, healthy, SweetBiotix. 

“As the food industry responds to growing public and political concerns over traditional sugars and artificial sweeteners, we expect growing interest in safer, healthy alternatives such as our SweetBiotix."

Ian_55ae0ddd437b7.jpg
Why Invest In OptiBiotix Health plc? Read More Here

Register here to be notified of future OPTI Company articles
View full OPTI profile

OptiBiotix Health plc Timeline

Related Articles

Benjamin Franklin wearing a medical mask
March 24 2016
Constellation has identified a significant market opportunity in healthcare billing management.
Venn-Life.jpg
October 04 2016
Innovenn owns and is developing Labskin, a living skin model and also has an anti-acne formulation.
Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.